Cargando…
LIX1 Controls MAPK Signaling Reactivation and Contributes to GIST-T1 Cell Resistance to Imatinib
Gastrointestinal stromal tumor (GIST), the most common sarcoma, is mainly caused by an oncogenic mutation in the KIT receptor tyrosine kinase. Targeting KIT using tyrosine kinase inhibitors, such as imatinib and sunitinib, provides substantial benefit; however, in most patients, the disease will eve...
Autores principales: | Ruiz-Demoulin, Salomé, Trenquier, Eva, Dekkar, Sanaa, Deshayes, Sébastien, Boisguérin, Prisca, Serrano, César, de Santa Barbara, Pascal, Faure, Sandrine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138740/ https://www.ncbi.nlm.nih.gov/pubmed/37108337 http://dx.doi.org/10.3390/ijms24087138 |
Ejemplares similares
-
LIX1 regulates YAP activity and controls gastrointestinal cancer cell plasticity
por: Guérin, Amandine, et al.
Publicado: (2020) -
LIX1 regulates YAP1 activity and controls the proliferation and differentiation of stomach mesenchymal progenitors
por: McKey, Jennifer, et al.
Publicado: (2016) -
LIX1-mediated changes in mitochondrial metabolism control the fate of digestive mesenchyme-derived cells
por: Guérin, Amandine, et al.
Publicado: (2022) -
Reintroduction of Imatinib in GIST
por: Reid, T.
Publicado: (2013) -
Novel roles for LIX1L in promoting cancer cell proliferation through ROS1-mediated LIX1L phosphorylation
por: Nakamura, Satoki, et al.
Publicado: (2015)